1	
2	Sources and pathways by which low-grade inflammation contributes to anaemia in rural African
3	children from 6 months to 3 years of age: study protocol for observational studies IDeA 1 and IDeA
4	2
5	
6	Elizabeth Ledger ¹ , Hans Verhoef ² , Amadou T Jallow ¹ , Nicole Cunningham ^{1,3} , Andrew M. Prentice ¹ ,
7	Carla Cerami ^{1*} .
8	
9	¹ Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine,
10	Atlantic Boulevard, Fajara, P.O. Box 273, Banjul, The Gambia
11	² Division of Human Nutrition and Health, Wageningen University, P.O. Box 17, 6700AA Wageningen,
12	The Netherlands
13	³ Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore,
14	MD, USA (current address)
15	
16	*Corresponding author: Dr Carla Cerami, email: <u>ccerami@mrc.gm</u>
17	Authors emails:
18	Elizabeth Ledger (elizabethledger@hotmail.com)
19	Hans Verhoef (<u>hans.verhoef@wur.nl</u>)
20	Amadou Jallow (<u>atjallow@mrc.gm)</u>
21	Nicole Cunningham (<u>ncunni11@jhmi.edu</u>)
22	Andrew M. Prentice (<u>aprentice@mrc.gm</u>)
23	Carla Cerami (<u>ccerami@mrc.gm)</u>
24	
25	

27 **ABSTRACT**

Background: Recent work suggests that persistent inflammation, even at low levels, could be more
 important than low dietary iron intake in the aetiology of iron deficiency and iron deficiency

30 anaemia (IDA) in young children living in poor environments.

31 Methods: We will conduct 2 parallel observational studies in well and unwell rural Gambian children 32 to identify the origins of chronic low-grade inflammation and characterise its relationship to iron 33 handling and iron deficiency anaemia. IDeA Study 1 will enrol 120 well children attending our regular 34 paediatric well-child clinics at 6, 12 and 18 months of age. IDeA Study 2 will enrol 200 sick children 35 suffering from upper-respiratory tract infection, lower respiratory tract infection, gastroenteritis or 36 urinary tract infection and study them on Days 0, 3, 7 and 14 after initial presentation. At each visit, 37 children will be assessed for signs of inflammation. Full blood count and iron-related biomarkers 38 (serum ferritin, serum iron, unsaturated iron-binding capacity, soluble transferrin receptor, 39 transferrin) will be measured before and after an oral dose of ferrous iron to assess status and acute 40 iron absorption. Inflammatory markers (C-reactive protein and α_1 -acid glycoprotein), hepcidin, 41 erythroferrone and erythropoietin will be measured to characterize the anaemia of inflammation in 42 these children.

- 43
- 44 **Conclusion:** We will assess the impact of acute and chronic low-grade inflammation on iron
- 45 absorption and investigate the hypothesis that chronic inflammation, juxtaposed on a poor diet,
- 46 causes a complex anaemia of inflammation which exacerbates iron deficiency by blocking both non-
- 47 haem iron absorption and iron utilization by the bone marrow.
- 48 **KEYWORDS:** Anaemia, anaemia of inflammation, low-grade inflammation, iron, The Gambia,
- 49 children, hepcidin, erythroferrone, erythropoietin, C-reactive protein
- 50 Clinical trial registry: ClinicalTrials.gov NCT04097639 and NCT04095884
- 51
- 52 Author approval: All authors have read and approved this manuscript.
- 53
- 54 55

56 BACKGROUND

57

58 consequent iron deficiency anaemia (IDA), is most prevalent in Sub-Saharan Africa and South Asia 59 [1]. The Global Burden of Disease estimates that 1.225 billion people suffer from IDA and the 60 consequent years lived with disability (YLDs) outweigh all other nutritional deficiencies, 61 haemoglobinopathies and haemolytic anaemias combined [1-2]. A 50% reduction in anaemia rates in 62 women of reproductive age is one of WHO's 6 key Global Targets for 2025. However, it has been 63 estimated that at current rates of progress this target will not be reached for 100 years. Similar 64 challenges exist for the rates of anaemia in children. 65 Effects of IDA

Iron deficiency (ID) is the most prevalent nutritional deficiency worldwide and, with its

66 Iron deficiency is a strong risk factor for adverse pregnancy outcomes including maternal 67 mortality. During foetal and child development, iron is required for diverse aspects of neural 68 formation, and deficiency is associated with delayed maturation of the brain and impaired cognition 69 [3,4]. Importantly, deficits occurring in these early critical windows leave children with permanent 70 damage that affects educational potential and hence human capital [5]. Iron deficiency may also 71 impair immune responses, especially cellular immunity, and hence may limit the effectiveness of 72 early childhood vaccines [6]. Interventions to correct ID face two interlocking challenges; potential 73 hazard and lack of efficacy.

74 Potential hazards of iron supplementation

75 The possible hazards of iron administration in LMICs arise from the fact that iron stimulates 76 the growth of many bacteria, protozoa and fungi [7]. Large epidemiological studies have shown that 77 ID protects against malaria and several RCTs have shown that administration of iron can increase the 78 risk of serious adverse outcomes in children (malaria, severe diarrhoea and respiratory tract 79 infections) leading to excess hospitalisations and deaths [8]. We have recently described the most 80 likely mechanism of how IDA protects against malaria, and how iron supplementation enhances the 81 risk [9,10]. We have demonstrated how acute iron administration enhances bacterial growth rates 82 [11,12]. These risks are driven at least in part by the use of non-physiological high doses of readily 83 absorbable iron thought necessary to overcome the lack of efficacy.

84 Efficacy of oral iron supplementation

85

The limited efficacy of iron administration is a universal problem across all iron 86 supplementation trials in LMICs and especially Africa. For example, we have recently completed 2

- 87 trials in rural Gambia with 400 children aged 6-24m [13,14] and 500 second trimester pregnant
- 88 women [12]. Despite administering iron for 12 weeks according to the WHO recommendations
- 89 (12mg/d to children and 60mg/d to pregnant women) with an additional 15 micronutrients and with

all doses taken under direct supervision, 45% of women at delivery and 75% of the children
remained anaemic [12,14]. Recent meta-analysis of 14 studies with 3011 patients found that iron
supplementation reduced the risk of anemia (defined as Hb <110g/dl) by 45% and increased mean
haemoglobin by 0.6g/l [15].

94 The role of hepcidin

95 The discovery of the hormone hepcidin, a largely liver-derived peptide that acts as a master 96 regulator of iron absorption and distribution, has yielded many new insights into the real-life biology 97 of iron, iron-related infections and anemia [16]. Hepcidin is down regulated by iron deficiency and 98 erythroid drive and up-regulated by iron sufficiency or overload and by inflammation [7,16]. 99 Hepcidin blocks iron absorption and recycling by down regulating ferroportin on the surface of 100 enterocytes and macrophages. Conversely low levels of circulating hepcidin promote duodenal 101 absorption of dietary iron, and permit rapid recycling of iron from aged or damaged erythrocytes.

102 Anaemia of inflammation

103 In patients with autoimmune disease, renal disease and cancer there is a well described 104 pathway to anaemia of inflammation where pro-inflammatory cytokines and upregulation of 105 hepcidin lead to a reduction in red cell production [17]. Our recent work has shown that persistent 106 inflammation (even at surprisingly low levels) could be more important than low dietary iron in the 107 aetiology of ID and IDA [18]. In the HIGH study [13] hepcidin and haemoglobin were measured 108 weekly and haematological, inflammatory and iron biomarkers were measured at baseline, 7 weeks 109 and 12 weeks in 407 anaemic (Hb <11g/dl) but otherwise healthy Gambian children (6-27 months). 110 Each child maintained a remarkably constant hepcidin level and half consistently maintained levels 111 that indicated physiological blockade of iron absorption. Hepcidin was strongly predicted by nurse-112 ascribed adverse events with dominant signals from respiratory infections and fevers [18]. In 113 multiple linear regression analysis, serum C-reactive protein (CRP) was the dominant predictor of 114 hepcidin and contributed to iron blockade even at very low levels. It was concluded that even low-115 grade inflammation was an important driver of IDA in rural African children.

Previous work has shown that iron incorporation was lower on Day 0 in children presenting with acute febrile malaria and on Day 15 of convalescence than in Hb-matched children with iron deficiency alone [19]. Subsequent analysis of the same data set revealed that hepcidin concentration best predicted iron incorporation [20]. In a study in Tanzanian children, hepcidin concentrations normalized by 4 weeks after treatment for malaria [21] and a recent study in Uganda found that children recovering from malaria incorporated more iron if they were given iron supplements starting 28 days after treatment for malaria than if given immediately [22]. The impact of other

infections on iron absorption is unknown and requires clarity to guide clinical strategies forenhancing iron absorption.

We hypothesise that chronic inflammation (even at low levels), juxtaposed upon a poor diet, causes anaemia of inflammation [17] which, by diverse possible pathways, exacerbates iron deficiency by blocking both non-haem iron absorption and iron utilization by the bone marrow (see **Figure 1**).

129 In our prior study it was not possible to define the source(s) of the low-grade chronic 130 inflammation because the children did not have detailed clinical examinations. The purpose of the 131 current studies is to locate the origin(s) of inflammation in apparently well and sick children. In the 132 cohort of well children their inflammation presumably arises from sub-clinical silent insults such as 133 skin infections, poor oral hygiene, gum disease, dental caries or gastrointestinal enteropathy. The 134 sick children will be recruited into 4 diagnostic categories representing the most common causes of 135 fever in this setting (now that the incidence of malaria has declined substantially); upper respiratory 136 tract infections (URTI), lower respiratory tract infections (LRTI), gastroenteritis and urinary tract 137 infections 138

139 Study objectives

140 The overarching goal is to clarify the relationship between chronic low-grade inflammation 141 and iron deficiency anaemia in rural African children. To this end the specific objectives are:

142

143 **IDeA Study 1**

1441)To confirm our prior observations that rural Gambian children frequently display persistent145inflammatory-mediated raised levels of hepcidin and to assess changes from 6-18 months of146age;

147 <u>2)</u> To seek to establish the likely source(s) of the persistent low-grade inflammation in 148 apparently well children living in rural Gambia between the ages of 6-18 months of age.

149 IdeA Study 2

- 1501) To seek to establish the likely source(s) of inflammation in sick children presenting to our151pediatric clinic in rural Gambia between 6-36 months of age with any of 4 diagnostic152categories; upper respiratory tract infections (URTI), lower respiratory tract infections (LRTI),
- 153 gastroenteritis or urinary tract infections (UTI).

154 <u>Secondary objectives for both studies</u>

- 155 1) To retest the existing hepcidin threshold of 5ng/ml (based on the Bachem ELISA; [23]) for 156 discriminating iron absorbers from non-absorbers by repeating our prior ROC analysis based 157 on a much larger sample;
- 158
 2) To establish the role of inflammation in the relationship between erythropoietin
 159 concentration (EPO) and haematological concentration s;
- 160 3) To describe the interrelationships between serum markers of systemic inflammation 161 (CRP/ α_1 -acid glycoprotein, AGP) and their associations with serum concentrations of 162 hepcidin and erythroferrone (ERFE);
- 163 4) To examine the influence of EPO on the association between haematological status and164 ERFE.
- 165

166 Rationale supporting the secondary objectives

Secondary objective 1: Using ⁵⁷Fe/⁵⁸Fe tracer studies of dietary iron utilisation in rural Gambian children [18,19] we previously determined that a threshold level of hepcidin (at 5.5ng/ml using the BACHEM ELISA) distinguished good iron absorbers from poor iron absorbers [23]. Although the ROC AUC was high at 0.90 this analysis has two limitations: a) it was based on a very small sample; and b) half of the children were recovering from an acute episode of malaria. This analysis will now be repeated to validate (or adjust) the threshold based on a much larger sample size and data from well children. Importantly our new dataset will allow us to test whether the threshold varies by age,

- anaemia status and at different levels of inflammation. Note that the threshold can be adjusted for
- 175 use with other hepcidin assays [24].
- 176 Secondary objective 2: We hypothesize that anaemic children with low-grade inflammation have an
- 177 anaemia of inflammation with concomitant iron deficiency that results in inappropriately low levels
- 178 of EPO production and reticulocytosis for their erythroid mass. Lack of responsiveness to EPO is an
- 179 important component and has been previously described in acute and convalescent malaria in
- 180 African children with high levels of inflammation [eg 25]. We will explore the relationship between
- 181 persistent lower grade inflammation and the production of EPO in desponse to anaemia. We will
- $182 \qquad \text{achieve this by establishing the role of inflammation in the relationship between EPO and} \\$
- 183 haemoglobin (as a measure of erythroid mass relative to total blood volume).
- 184 Secondary objectives 3 and 4: Erythroferrone is the recently-discovered hormone that mediates
- 185 hepcidin suppression during stress erythropoiesis [26,27]. First, we will conduct a hypothesis-free
- 186 exploratory analysis to assess whether ERFE behaves as predicted based upon mouse models (i.e. is

- 187 up-regulated by stress erythropoiesis and inversely related to hepcidin). As summarised in **Fig 1** we
- 188 hypothesise that there may be a vicious cycle initiated by inflammation and then perpetuated by the
- 189 consequent low levels of (iron-restricted) erythropoiesis, leading to low ERFE and loss of hepcidin
- 190 suppression.

191 SUBJECTS AND METHODS

192 Study setting

- 193 MRC The Gambia Keneba field station is situated in rural West Africa where there are 194 dramatic seasonal shifts from wet to dry seasons and where the majority of the population are 195 subsistence farmers. The field station runs a well-accessed free primary health care facility and also 196 is the home of the Keneba Biobank Project which contains blood samples from consenting 197 individuals in 36 villages with 96% participation [28]. Analysis of over 4,000 samples from the 198 biobank revealed a prevalence of anaemia (as per WHO definition haemoglobin less than 11g/dl) of 199 91% in under-2 year olds and 71% in 2-3 year olds, with 78% of this anaemia (based on MCV cut off 200 70 fL) derived from well-nourished African American children) caused by iron deficiency 201 (unpublished analysis). Children from the 3 closest villages to the Keneba clinic (Keneba, Kantong 202 Kunda and Manduar) will be recruited when they present for vitamin A supplementation and well-
- 203 child check-up at 6 months of age, or when self-presenting with an acute infection.

204 Recruitment and procedures for IDeA Study 1

205 Study design

- 206 This is a prospective cohort study of children who will enroll at the age of 6-8 months, with a follow-
- 207 up period of one calender year from recruitment onwards. A total of 120 well children will be
- 208 recruited from weekly vaccination call clinics. After informed consent is obtained, children will have
- 209 to meet the following inclusion/exclusion criteria to be enrolled.
- 210

211 Inclusion/exclusion criteria

212 Children must be aged between 6-8 months at the time of study enrolment, residing in and 213 intending to stay in the study site area and willing to adhere to all protocol visits and procedures, 214 free from acute illness, with a normal temperature (<37.5 degrees Celsius), with no vaccinations in 215 the last 7 days prior to study enrolment, with no recent administration of immune-suppressants or 216 other immune-modifying agents within 90 days prior to study, with no administration of systemic 217 antibiotic treatment within 3 days prior to study enrolment, with no history of, or evidence for, 218 chronic clinically significant disorder or disease, with no history of maternal infections by human

immunodeficiency virus, chronic hepatitis B or chronic hepatitis C, and not participating in anotherstudy.

A field worker will be responsible for maintaining links with participants between follow up visits and arranging transport to and from the study site. Scheduling will be arranged through the REDCap software system (REDCap; https://projectredcap.org).

224 Participant flow

We expect to enrol 10 participants per month over one calendar year so that the target sample size (120 children) will be attained in one year. Each participant will be seen three times, at times when they would usually present to clinic as part of The Gambia EPI schedule: 6 months, 12 months (Diptheria, Petussis and Tetanus boosters) and 18 months (Polio, Measles and Rubella boosters). All patients will be seen and take part in the iron absorption test before receiving routine immunisation.

231 Clinical assessment

At each visit, children will be examined by the research clinician using pre-determined checklists for possible sources of low-grade inflammation (**Tables 1**).

234 A clinical score has been devised based on a number of clinical severity scores for certain 235 minor illnesses of childhood and takes into account severity of symptom/condition and the number 236 of anatomical sites affected. Sources of inflammation and infection will be searched for in the ears, 237 nose and throat, the respiratory system, the skin and all skin flexures, the oral cavity including 238 dentition, evidence of lymphadenopathy, signs of infection/inflammation in the orbital region and 239 any evidence of injury or trauma. Severity is graded as 0- normal/no inflammation; 1- mild 240 inflammation; 2- moderate inflammation; 3- severe inflammation. Existing validated clinical scores 241 developed to guide management and treatment were used and adapted for diagnoses of otitis 242 externa [29], otitis media [30], lower respiratory tract infections [31], and atopic dermatitis [32]. 243 Where clinical scores do not exist, divisions of severity will be made based on clinical findings such as 244 number of lesions or extent of erythema. The number of anatomical locations and severity of the 245 signs found is added together to give a numerical score with a range 0-81 (severe inflammation at 27 246 possible anatomical sites).

Skin conditions, poor oral health, and respiratory infections/airway disease are very common in children in West Kiang, particularly in the rainy season, but are not usually considered serious enough by the parents to bring the child to clinic. Possible skin sources of inflammation include eczema, impetigo, folliculitis, and fungal infections such as tinea capitis will be noted if present.

- 251 Although gingivitis and dental caries are rare in UK children of this age, poor oral hygiene in the
- 252 Gambian population Is a potential source of inflammation [33,34].

253 Recruitment and procedures for IDeA Study 2

254 Study design

In total, 200 sick children aged between 6-36 months will be recruited from the clinic.
Successive children brought by their mothers to the clinic will be recruited into 4 diagnostic
categories; upper respiratory tract infections, lower respiratory tract infections, gastroenteritis and
urinary tract infections. These reflect the commonest causes of fever in this age range [35,36]. Fever
is the commonest presenting complaint to the Keneba clinic in this age range. Each participant will
be seen 4 times: Days 0, 3, 7 and 14 after initial presentation. After informed consent is obtained,
children will have to meet the following inclusion/exclusion criteria to be enrolled into the study.

262 Inclusion/exclusion criteria

263 For inclusion, children must be aged between 6-36 months at the time of study enrolment, 264 residing in and intending to stay in the study site area and willing to adhere to all protocol visits and 265 procedures, with a fever (>37.5C) and/or signs of acute illness, with no vaccinations in the last 7 days 266 prior to study enrolment, with no recent administration of immune-suppressants or other immune-267 modifying agents within 90 days prior to study, with no administration of systemic antibiotic 268 treatment within 3 days prior to study enrolment, with no history of or evidence for chronic clinically 269 significant disorder or disease, with no maternal history of human immunodeficiency virus, chronic 270 hepatitis B or chronic hepatitis C infections, and not participating in another study.

In addition to this they must fall into one of the four following diagnostic categories as definedbelow.

273 Urinary tract infection (UTI) [37]

- 274 Inclusion criteria (one from the list below):
- 275 1. Positive leucocytes, positive nitrites on dipstick
- 276 2. Negative leucocytes, positive nitrites on dipstick
- 277 3. Positive leucocytes, negative nitrites, plus bacteriuria on microscopy
- Positive leukocytes, negative nitrites plus no bacteriuria, only pyuria on microscopy PLUS
 clinical features e.g. fever, pain on urination, offensive smelling urine.
- 280 Lower respiratory tract infections (LRTI) [38]
- 281 Inclusion criteria (one from the list below):
- 1. Focal signs on auscultation of the chest i.e. crepitations/ wheeze/ reduced air entry

- 283 2. Fever > 38.5C AND chest recessions AND/OR respiratory rate over 40 breaths/minute
- 284 3. Radiological evidence of LRTI
- 285 Exclusion criteria:
- 286 1. Positive malaria test OR suspicion of metabolic acidosis causing tachypnoea and fever
- 287 Upper respiratory tract infection (URTI) [39]
- 288 Inclusion criteria (one from the list below):
- 289 1. Evidence of nasal discharge AND/OR
- 290 2. Inflammation throat/ tonsils on direct examination AND/OR
- 291 3. Inflammation of middle or outer ear on direct examination
- 292 4. History of fever AND history of stridor/ barking cough
- 293 5. History of fever AND lymphadenopathy AND/ OR URTI symptoms i.e. sore throat/cough
- 294 Exclusion criteria (one from the list below):
- 295 1. Foreign body inserted in either nose/ ear
- 296 2. Traumatic perforation of ear drum
- 297 3. Allergic rhinitis i.e. good contact history
- 298 4. Evidence of LRTI

299 Diarrhoea/gastroenteritis [39]

- 300 Inclusion criteria (one from the list below):
- 301 1. Abrupt onset of 3 or more loose/liquid stools/ day
- 302 2. Ova, cysts, parasites identified on stool microscopy PLUS (diarrhoea or fever or vomiting)
- 303 3. Fever AND vomiting WITHOUT other cause of fever i.e. UTI/LRTI/URTI
- 304 Exclusion criteria (one from the list below):
- **1.** Neurological cause of vomiting

306 Withdrawal of participants

- 307 In case the participant decides to withdraw during either study, the participant's samples will not be
- 308 worked on, but any information previously generated from the samples before the time of
- 309 withdrawal will be used.

310 Oral iron absorption test

311 After the clinical examination, an oral iron absorption protocol will be initiated in all children:

- 312 <u>Step 1</u>: A baseline venous blood sample will be collected for later assay of full blood count (including
- reticulocyte count) and serum iron markers, hepcidin, erythropoietin (EPO), erythroferrone, IL-6 and
- 314 EndoCab;
- 315 <u>Step 2</u>: Children will be given an oral dose of liquid ferrous fumarate at 2mg/kg;
- 316 Step 3: 4 hours later a venous blood sample will be drawn for measurement serum iron markers. The
- 317 change in serum iron levels (measured before and after dosing) will be used as a direct
- 318 measurement of iron absorption.

319 Laboratory analysis

Whole blood samples will be assessed for: full haematology panel (using a Medonic M2OM GP
or Cell Dyne Ruby). All serum samples collected will be assessed for the following: hepcidin,
erythropoietin, erythroferrone all by ELISA. Additionally, serum ferritin, serum iron, unsaturated
iron-binding capacity (UIBC), soluble transferrin receptor (sTfR), transferrin, C-reactive protein (CRP),
and alpha 1-acid glycoprotein (AGP) will be assessed using a fully automated biochemistry analyser
(Cobas Integra 400 plus).

A stool sample will be collected to check for presence and severity of helminth infection and
 analysed for fecal calprotectin as a marker of gut inflammation or environmental enteric dysfunction
 (EED).

329 Data entry, handling, storage and security:

All protocol-required field data will be captured electronically on an electronic Case Report Form (eCRF). Data will be entered in real time using eCRFs developed in a REDCap (Research Electronic Data Capture) database. Entered data will be acquired by the database via a direct secure connection over the 4G mobile network. Laboratory related data will be extracted directly from laboratory equipment, where functionality is available and uploaded to the database. Otherwise, results will be captured using a custom designed laboratory results form. Any data collected on the paper format will be double entered by a trained data entry clerk.

After giving written consent, the children will be given a study identification number, which will be used in all future datasets for subject anonymity. Any and all paper/electronic forms will be checked and any errors will be identified prior to marking data as complete. Electronic data will be stored on the local dedicated server maintained at MRCG. The study will be conducted in compliance with Good Clinical Practice. Study personal security measures will include controlled access limited to authorised users only, physical security, removal of identifiable information

- 343 (anonymization) prior to any data sharing, avoidance of third-party cloud storage and password
- 344 protection.

345 Sample size calculation

- 346 The primary objective is a descriptive study. No sample size calculation was conducted.
- 347 Statistical analysis:

348 **Primary objective:**

349 The primary objective of this study is to determine the sources of low-grade inflammation in 350 otherwise-well children between the ages of 6-24 months living in rural Gambia.

351 Analysis plan:

- 352 Multiple regression analysis will be used to model inflammatory markers (serum
- 353 concentrations of CRP and AGP) as a function of clinical scores for skin infections, oral health and
- 354 respiratory infections; and stool markers of inflammation (fecal calprotectin). In these analyses, we
- 355 will account for child age as a potential confounder, and we will account for multiple assessments
- 356 for each child.

357 Secondary objective 1:

- 358 To retest the hypothesis that falling hepcidin concentrations predict a rise in serum iron absorption
- in a much larger sample size.
- 360 Analysis plan:
- 361 Multiple regression analysis will be used to model iron absorption (serum iron concentration
- 362 at 3h after oral administration of the iron supplement) as a function of hepcidin concentration.
- 363 Because we expect the serum iron response to strongly depend on serum iron concentration before
- administration of the iron dose), we will include initial serum iron concentration as a covariate in the
- 365 model (both as main term and its product term with hepcidin concentration). We will also assess the
- 366 role of other potential effect modifiers (age, anaemia, CRP, AGP, sTfR, MCV, EPO and
- 367 erythroferrone), each in separate models, using a backwards elimination process.

Secondary objective 2:

- 369 To establish the role of inflammation in the relationship between EPO and haematocrit to test
- 370 for decreased EPO synthesis and/or increased EPO resistance in anaemic children with low-grade
- inflammation.

372 Analysis plan:

373 In the absence of anaemia, EPO concentrations are low (approximately 10U/L) and 374 independent of haemoglobin concentration, consistent with our biological understanding that EPO is 375 produced only in response to hypoxic stress. In anaemia, however, EPO production may increase by 376 a factor of up to 1000, with the increase in log EPO being linearly associated with haemoglobin 377 concentration (or its proxy, haematocrit values). The slope of the regression line between log EPO 378 and haemoglobin concentration is reduced in patients with inflammation compared to their peers 379 with moderate to severe deficit of functional iron. In iron deficiency without inflammation, it is 380 believed that there are no restrictions in EPO production other than its response to hypoxia. 381 Together, this evidence indicates that, in inflammation, the EPO response is inappropriately low for 382 the degree of anaemia.

The challenge in our analysis will be to similarly show the influence of inflammation (indicated by serum concentrations of CRP or AGP) on the association between EPO and haemoglobin concentration. Because the degree of inflammation is expected to be lower than in the patients studied in previously published reports, and because haemoglobin concentration is expected to be higher, we expect much smaller effects.

388 We will assess influences on EPO using fractional polynomial regression models with CRP and 389 AGP (continuous variables) and haemoglobin concentration (continuous variable centred at 110g/L), 390 as well as their product terms, whilst accounting for dependency of observations within persons and 391 potential heteroscedasticity:

392

393

$$\hat{InEPO} = \beta_0 + \beta_1 \cdot (Hb - 110) + \beta_2 \cdot CRP + \beta_3 \cdot AGP + \beta_4 \cdot [(Hb - 110) \cdot CRP] + \beta_5 \cdot [(Hb - 110) \cdot AGP]$$

394 where Hb indicates haemoglobin concentration in g/L. Analysis will be restricted to individuals with 395 anaemia (haemoglobin concentration \leq 110g/L). We expect to be able to eliminate the main terms 396 for CRP and AGP from this model, under the assumptions that inflammation does not lead to a 397 reduction in EPO concentration unless it is accompanied by a reduction in haemoglobin 398 concentration below 110g/L, and that inflammation is adequately and entirely represented by CRP 399 and AGP. In such conditions, inflammation will influence the slope of the line between log EPO and 400 haemoglobin concentration, but not its intercept (i.e., at haemoglobin concentrations of 110g/L, our model above will reduce to a single expected value: $EPO = e^{\beta_0}$). Thus, our model is parametrised to 401 402 allow evaluation of our hypothesis that inflammation reduces EPO response to haemoglobin 403 concentration (β_4 and β_5 are both below zero).

404 In an analysis of all data combined, the potential effect modification by CRP (and alternate 405 measures of iron status and inflammation including hepcidin) will be assessed using forward 406 selection to determine the variables for inclusion in multivariate analysis of factors predicting the 407 slope and intercept of the EPO/Hb relationship. We will also calculate the Reticulocyte Production 408 Index (RPI) = (Hct/45)*Retic/Maturation. An RPI >3 shows a normal marrow response to anemia. 409 An RPI <2 is an inadequate response to anemia and is consistent with a diagnosis of AI. Additionally, 410 because serum sTfR levels are the product of cellular receptor density (and are up-regulated by iron 411 demand) and cell numbers (primarily deemed to reflect erythroblasts) we will conduct an 412 exploratory analysis of the inter-relationships between EPO, sTfR and reticulocyte number. 413

414 Secondary objectives 3 and 4:

To describe the interrelationships between: a) systemic inflammation (CRP/AGP) and its
associations with hepcidin and ERFE, and b) the influence of EPO on the association between Hb and
ERFE.

418 Analysis plan:

419 We will conduct a hypothesis-free exploratory analysis to assess whether ERFE behaves as 420 predicted based by mouse models (ie up-regulated by stress erythropoiesis and inversely related to 421 hepcidin). Our first task will be to map and explore the inter-relationships between ERFE and the 422 erythroid drive (reticulocytes, sTfR and EPO) and to examine whether there is evidence that ERFE is 423 significantly modulating hepcidin. This will require multiple regression modelling and pathways 424 analysis that include the competing stimuli for which prior analysis suggest that UIBC and MCV will 425 be the best indices of iron status and CRP/AGP and granulocyte counts the best indices of 426 infection/inflammation. Depending upon the outcomes of these exploratory analyses we may be 427 able to test our hypothesis that the high levels of hepcidin so common in Gambian children are 428 driven in part by suppressed ERFE.

429 Confounding, bias and loss to follow up

The study design does not provide for the recruitment of equal numbers of subjects in each month of the year (or during the dry vs wet seasons). If we are missing data for the covariates, for the secondary analysis, we will use pairwise deletion and consider multiple imputation if there are missing covariates in more than 5% of participants and data can be assumed to be missing at random. If loss to follow-up rate is considerably different between groups, we will perform sensitivity analyses to examine the robustness of results.

437 **DISCUSSION**

- 438 Iron deficiency and iron deficiency anaemia remain significant public health concerns in children in
- 439 The Gambia and similar LMICs. Programmes to combat iron deficiency are frequently unsuccessful
- 440 due to poor efficacy of oral iron supplementation and potential hazards in certain circumstances. We
- 441 have previously shown that the low-grade inflammation frequently found in children living in
- 442 unsanitary environments can result in hepcidin-mediated blockade of iron absorption. This project
- 443 will try to identify the sources of this low-grade inflammation in seemingly 'well' Gambian children
- 444 and assess its severity in unwell children. It will additionally try to understand the complex
- 445 interacting mechanisms linking inflammation, hepcidin, EPO and ERFE to iron absorption,
- 446 distribution and erythropoiesis. If, as we speculate, the origins of IDA are more strongly determined
- 447 by inflammation than by low dietary iron this would have important implications for future clinical
- 448 interventions as well as agricultural and livestock policies.

449

450

451

453 Abbreviations

- 454 AGP: alpha-1-acid-glycoprotein; CRP: C-reactive protein; ELISA: enzyme-linked immunosorbent
- 455 assay; EndoCAB: serum endotoxin core antibody; EPO: erythropoietin; ERFE: erythroferrone; Hb:
- 456 haemoglobin; ID: iron deficiency; IDA: iron deficiency anaemia; iFABP: enterocyte fatty acid binding
- 457 protein; IL-6; interleukin 6; IRIDA; iron refractory iron deficiency anaemia; LMIC: lower middle
- income country; MCV: mean cell volume; REG1b: regenerating protein 1 beta; RPI: retriculocyte
- 459 production index; ROC AUC: area under the receiver operating characteristic curve; sTfR: soluble
- 460 transferrin receptor; UIBC: unsaturated iron-binding capacity; WHO: World Health Organisation.

461 Acknowledgments

- 462 We thank the Dr Fatai Akemokwe and Edrisa Sinjanka for their guidance and enthusiasm during the
- 463 planning this study.

464 Funding

- 465 This research is undertaken with a research grant provided by the Medical Research Council
- 466 (MR/R023360/1) with additional core funding to the MRC Unit The Gambia @ LSHTM from the UK
- 467 Medical Research Council (MRC) and the UK Department for International Development (DFID)
- 468 under the MRC/DFID Concordat agreement. The funding agencies had no role in the design and
- 469 conduct of the study, and will not have any role in the collection, management, analyses or
- 470 interpretation of the data nor in the preparation, review, or approval of the manuscript.

471 Availability of data and materials:

- 472 All data will be made available to researchers upon reasonable request to the study PI and clearance
- 473 by the MRCG Scientific Coordinating and Ethics Committees.

474 Authors contributions

- 475 AMP and CC conceived the study. EL and CC designed the clinical study protocol. EL, CC, ATJ
- 476 developed the laboratory protocols. HV wrote the data analysis plan in consultation with CC and
- 477 AMP. EL, NC, CC and AMP drafted the manuscript. All authors approved the manuscript.
- 478

479 Ethics approval and consent to participate

- 480 These studies have been approved by The Gambia Government/MRC Joint Ethics Committee (LEO
- 481 1664 and 17079). The study procedures will be explained to the children's mothers/guardians orally

- 482 with a witness present if they are illiterate or in writing. A child will be recruited into the study after
- 483 the consent form has been signed/thumb printed by the mother/guardian.
- 484

485 Future use of stored specimens

- 486 The blood and faecal samples collected during the trial may be used to support other research in the
- 487 future, and may be shared anonymously with other researchers, for their ethically approved
- 488 projects. Any future use would require approvals from the principal investigator, MRCG@LSHTM
- 489 Scientific Coordinating Committee, and the Gambian Government MRCG Joint Ethics Committee.
- 490 Informed consent from the parents/guardians for this will be included within the informed consent
- documents.

492 Participant confidentiality

- 493 Any identifiable data collected will be stored securely and their confidentiality protected in
- 494 accordance with the UK General Data Protection Regulation (UK GDPR) and the Data Protection Act
- 495 (2018). All data will be anonymised, and individuals will not be identifiable.

496 Dissemination and data availability

- 497 All key findings from this study will be submitted for publication in peer-reviewed journals. Any
- 498 request for use of study data will go through approval from the Scientific Coordinating Committee at
- 499 MRC Unit The Gambian and the Gambian Government MRCG Joint Ethics Committee. All data will be
- 500 in an anonymous format for external users.
- 501 **Consent for publication:**
- 502 Not applicable.
- 503
- 504 **Competing interests:**
- 505 The authors declare that they have no competing interests.
- 506


507	References	
508	1. James SL et al. Global, regional, and na	tional incidence, prevalence, and years lived with
509	disability for 354 diseases and injuries	for 195 countries and territories, 1990–2017: a
510	systematic analysis for the Global Burd	en of Disease Study 2017. The Lancet. 2018;392:1789-
511	1858.	
512	2. Hess SY, McLain AC, Frongillo EA, Afshi	n A, Kassebaum NJ, Osendarp SJM, Atkin R, Rawat R,
513	Brown KH. Challenges for Estimating th	e Global Prevalence of
514	Micronutrient Deficiencies and Related	Disease Burden: A Case Study of
515	the Global Burden of Disease Study. Cu	rr Dev Nutr. 2021;5:nzab141.
516	3. Cusick SE & Georgieff MK. The Role of	Nutrition in Brain Development: The Golden
517	Opportunity of the "First 1000 Days." J	Pediat. 2016;175:16-21.
518	4. Georgieff MK, Ramel SE, Cusick SE. Nut	ritional influences on brain development. Acta
519	Paediatr. 2018;107:1310-1321.	
520	5. Horton S, & Ross J. The economics of ir	on deficiency. Food Policy. 2003;28:51-75.
521	6. Drakesmith H, et al. Vaccine efficacy ar	nd iron deficiency: an intertwined pair? Lancet
522	Haematol. 2021;8:e666-e669.	
523	7. Drakesmith H & Prentice AM. Hepcidin	and the iron-infection axis. Science. 2012;338:768-
524	72.	
525	8. Prentice AM, Mendoza YA, Pereira D, C	erami C, Wegmuller R, Constable A & Spieldenner J.
526	Dietary strategies for improving iron st	atus: Balancing safety and efficacy. Nutrition
527	2017;75:49-60.	
528	9. Clark MA et al. Host iron status and iro	n supplementation mediate susceptibility to
529	erythrocytic stage plasmodium falcipar	um. Nat Comms. 2014;5:4446
530	10. Goheen MM, et al. Anemia Offers Stro	nger Protection Than Sickle Cell Trait Against the
531	Erythrocytic Stage of Falciparum Malar	ia and This Protection Is Reversed by Iron
532	Supplementation. EBioMedicine. 2016	14:123-130
533	11. Cross JH, Bradbury RS, Fulford AJ, Jallo	w AT, Wegmüller R, Prentice AM & Cerami C. Oral iron
534	acutely elevates bacterial growth in hu	man serum. Scientific Reports. 2015;5:16670
535	12. Bah A, et al. Hepcidin-guided screen-ar	nd-treat interventions against iron-deficiency anaemia
536	in pregnancy: a randomised controlled	trial in The Gambia. Lancet Glob Health.
537	2019;7:e1564-e1574.	
538	13. Wegmüller R et al. Efficacy and safety of	of hepcidin-based screen-and-treat approaches using
539	two different doses versus a standard	universal approach of iron supplementation in young
540	children in rural Gambia: A double-blin	d randomised controlled trial. BMC Pediatrics.

2016;16:149.

542 14. Wegmüller R, Bah A, Kendall L, Goheen MM, Sanyang S, Danso E, Sise EA, Jallow A, Verhoef 543 H, Jallow MW, Wathuo M, Armitage AE, Drakesmith H, Pasricha SR, Cross JH, Cerami C, 544 Prentice AM. Hepcidin-guided screen-and-treat interventions for young children with iron-545 deficiency anaemia in The Gambia: an individually randomised, three-arm, double-blind, 546 controlled, proof-of-concept, non-inferiority trial. Lancet Glob Health. 2023;11:e105-e116. 547 15. Tam E, Keats EC, Rind F, Das JK, Bhutta AZA. Micronutrient Supplementation and 548 Fortification Interventions on Health and Development Outcomes among Children Under-549 Five in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. 550 Nutrients. 2020;12:289. 551 16. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721-41. 552 17. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;3:133:40-50. 553 18. Prentice AM et al. Respiratory infections drive hepcidin-mediated blockade of iron 554 absorption leading to iron deficiency anemia in African children. Science Advances. 555 2019;5:eaav9020 556 19. Doherty CP, Cox SE, Fulford AJ, Austin S, Hilmers DC, Abrams SA, Prentice AM. 557 Iron incorporation and post-malaria anaemia. PLoS One. 2008;3:e2133. 558 20. Prentice AM, et al. Hepcidin is the major predictor of erythrocyte iron incorporation in 559 anemic African children. Blood. 2012;119:1922-8. 560 21. de Mast Q, et al. Assessment of urinary concentrations of hepcidin provides novel insight 561 into disturbances in iron homeostasis during malarial infection. J Infect Dis. 2009199:253-562 62. 563 22. Cusick SE, Opoka RO, Abrams SA, John CC, Georgieff MK, Mupere E. Delaying Iron Therapy 564 until 28 Days after Antimalarial Treatment Is Associated with Greater Iron Incorporation and 565 Equivalent Hematologic Recovery after 56 Days in Children: A Randomized Controlled Trial. J 566 Nutr. 2016;146:1769-74. 567 23. Pasricha SR et al. Expression of the iron hormone hepcidin distinguishes different types of 568 anemia in African children. Sci Trans Med. 2014;6:235re3. 569 24. van der Vorm LN et al. Toward worldwide hepcidin assay harmonization: Identification of a 570 commutable secondary reference material. Clin Chem. 2016;62:993-1001. 571 25. Kurtzhals JA, Rodrigues O, Addae M, Commey JO, Nkrumah FK, et al. Reversible suppression 572 of bone marrow response to erythropoietin in Plasmodium falciparum malaria. Br J 573 Haematol 1997;97:169-174.

574	26.	Kautz L, Jung G, Valore EV, Rivella S, Nemeth E & Ganz T. Identification of erythroferrone as
575		an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678-84
576	27.	Pasricha S-R, McHugh K & Drakesmith H. Regulation of Hepcidin by Erythropoiesis: The Story
577		So Far. Ann Rev Nutr. 2016;36:417-34
578	28.	Hennig BJ, et al. Cohort Profile: The Kiang West Longitudinal Population Study (KWLPS)-a
579		platform for integrated research and health care provision in rural Gambia. Int J Epidemiol.
580		2012;46:e13
581	29.	Hajioff D & Mackeith S. Otitis externa. BMJ Clin Evid. 2015;2015:0510
582	30.	Casey JR, Block S, Puthoor P, Hedrick J, Almudevar A & Pichichero ME. A simple scoring
583		system to improve clinical assessment of acute otitis media. Clin Ped. 2011;50:623-9.
584	31.	Rodriguez H, Hartert TV, Gebretsadik T, Carroll KN & Larkin EK. A simple respiratory severity
585		score that may be used in evaluation of acute respiratory infection Pediatrics. BMC Research
586		Notes. 2016;9:85.
587	32.	Wolkerstorfer A, De Waard van der Spek FB, Glazenburg EJ, Mulder PGH & Oranje AP.
588		Scoring the severity of atopic dermatitis: Three item severity score as a rough system for
589		daily practice and as a pre-screening tool for studies. Acta Dermato-Venereologica.
590		1999;79:356-9.
591	33.	Gordon N. Oral health care for children attending a malnutrition clinic in South Africa. Int J
592		Dent Hyg. 2007;5:180-6
593	34.	Lamb WH & Prentice AM. A prospective survey of gingivitis in Keneba, a rural West African
594		community. Annals of Tropical Paediatrics. 1983;3:137-42.
595	35.	D'Acremont V et al. Beyond malaria - Causes of fever in outpatient Tanzanian children. New
596		Engl J Med 2014;370:809-17.
597	36.	Davis T. NICE guideline: Feverish illness in children - Assessment and initial management in
598		children younger than 5 years. Arch Dis Childh: Educ Pract Ed. 2013;98:232-5.
599	37.	NICE. (NICE) Urinary tract infection in under 16s Diagnosis and management. National
600		Institute for Health and Care Excellence (2007).
601	38.	Harris M et al. British Thoracic Society guidelines for the management of community
602		acquired pneumonia in children: Update 2011. Thorax 2011;66 Suppl 2:ii1-23
603	39.	World Health Organization. Guideline: Updates on Paediatric Emergency Triage, Assessment
604		and Treatment: Care of Critically-III Children. Guideline: Updates on Paediatric Emergency
605		Triage, Assessment and Treatment: Care of Critically-Ill Children (2016).
606 607		
608		

- 610 Figure 1: Pathways by which inflammation in young children contributes to an anaemia of
- 611 inflammation



- 614 IL-6, interleukin-6 (and related inflammatory signals); ERFE, erythroferrone; EPO, erythropoietin

617 Table 1: Clinical Score of Site and Severity of Infection and Inflammation (CSSSII)

System	Sign/Diagnosis	Site	Severity score Normal (0), mild (1), moderate (2), severe (3)
Lymphadenopahty		Neck, axilla, groin, other	0 None (0); 1 1 node < 1cmd, rubbery (1); 1-3 nodes,rubbery (2); > 3nodes, any node > 1cm, any node hard or evidence of suprainfection (3).
Ears	Otitis externa	Right, left	Normal (0); TM seen, canal erythematous (1); Oedematous canal, debris in canal, TM obscured (2) Fever, oedmetous ear canal, cellulitis of pina (3)
	Otitis media	Right, left	Normal (0); Retracted/neutral position of TM, mild erythema (1), Moderate TM erythema, TM mobility decreased (2), Full, bulging TM, otorrhoea, severe TM erythema, TM mobility absent (3)
Nose	Discharge		None (0); Clear (1); Purulent (2); Profuse, purulent and/ or bloody (3)
Throat		Right, left	Normal (0); Mild In\$ammation (1); Infammation and exudate (2); Severe infammation and swelling exudate/pus/abscess (3)
Respiratory	Presence of interval symptons (asthma)		No interval symptoms (0); Night time cough, shortness of breath o exertion, or family history, or previous use of inhaler (1); Diagnosed asthma and regular use of inhaler (2) Use of inhalers every day/ active Use of inhalers every day/ active flair up up currently
	Oxygen saturations		0 >95% (0); 94-95% (1); 90-93% (2); < 90% (3)
	Tachypnea		None (0); Mild intercostal retractions (1); Moderate intercostal retractions(2); Severe, head bobbing, tracheal tugging (3)
	Auscultation		No added sounds (0) End expiratory wheeze/ creps only (1) Few scattered/ focal crepitations. Focal reduced air entry (2); Coarse crepitations throughout both lung fields, reduced air entry throughout both lung fields (3)
Skin	Scabies		None (0); < 10 lesions (1); 11-49 lesions (2); > 50 lesions or crusted scabies (3)
	Impetigo		None (0) 1 1-10 lesions (1) 2 11-49 lesions (2) 3 > 50 lesions or associated with
			any systemic symptoms (fever, vomiting, rigors)(3)
	Atopic dermatitis		None (0); Less 5% BSA involved, no acute changes, no signilcant impact on quality of life (1); 5-30% BSA involved, mild dermatitis with acute changes, mild dermatitis with signilcant impact on Quality of Life (QoL) (2) >30% BSA, Mod dermatitis with acute changes, Mod dermatitis with signilcant impact on Quality of Life (3)
	Oral thrush		None (0); White coated tongue, mouth (1); Red painful to eat/swallow (2); Evidence of oesophageal involvement (3)
	Tinea		None (0); One plaque (1); 2-5 plaques (2); > 5 plaques (3)
	Nappy Rash		None (0); Mild erythema/ papules (1); Broken skin, severe erythema (2); Suprabacterial infection (3)
	Helminths		None (0); Larva currens (1); Larva migrans (2); Larva migrans with systemic features (3)
	Trauma		None (0); 1-2 bruise or super!cial scratch < 5cm diameter 2,(1); single bruise or deeper lacerations 5-10cm d or multiple super!cial wounds in 2- 10 locations (2); Bruise/ laceration >10cm d or greater than 10 discreet areas (3)
Eyes	Infection		None (0);Discharge/ mild conjunctivitis in one eye (1); Discharge/ conjunctivitis in both eyes (2); Periorbital or orbital cellulitis (3)
Dental	Gingivitis		None (0); Mild erythmema, swelling and bleeding of gums (1); Moderate erythema, swelling, bleeding and signs of infection (2);Severe erythema, swelling, bleeding and infection in gums (3)
	Number of decayed		None (0); 1-2 decayed teeth (1); 2-5 (2); 3 >5 (3)
	Mouth and mucous membranes		None (0); Angular stomatitis (1); Herpes lesions 1-2 (2) 3 or more herpes lesions or similar (3)